Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
Inhalt bereitgestellt von PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Player FM - Podcast-App
Gehen Sie mit der App Player FM offline!
Gehen Sie mit der App Player FM offline!
Ruben A. Mesa, MD, FACP - Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms and Emerging Therapeutics
M4V•Episode-Home
Manage episode 373556786 series 1118501
Inhalt bereitgestellt von PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.
…
continue reading
66 Episoden
Ruben A. Mesa, MD, FACP - Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms and Emerging Therapeutics
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
M4V•Episode-Home
Manage episode 373556786 series 1118501
Inhalt bereitgestellt von PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.
…
continue reading
66 Episoden
Todos los episodios
×Willkommen auf Player FM!
Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.